趋化因子CCL21在抗肿瘤免疫中的研究进展

Progress in research and application of CCL21 in anti-tumor immunity

趋化因子CCL21是CC型趋化因子家族成员,因具有趋化并激活树突状细胞(DCs)及免疫效应细胞的功能而被应用在抗肿瘤研究及临床治疗中.随后,不断出现基于CCL21的各种免疫治疗策略和措施,有效地增强了机体的抗肿瘤作用.本文对CCL21的抗肿瘤免疫机制及应用作一综述,旨在为进一步深入研究及临床应用提供参考.

CCL21, a member of the CC-type chemokine family, has been used in anti-tumor research and clinical treatment because of its chemotaxis and activation of dendritic cells ( DCs) and immune effector cells. Since then, effective immunotherapeutic strategies and improvements based on CCL21 have emerged to enhance anti-tumor effects. This article summarizes the anti-tumor immune mechanism and application of CCL21 to provide reference for further research and clinical application.